Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-09-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
自愿披露关于GB10注射液临床试验注册申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by the company regarding the acceptance of a clinical trial registration application for a new drug (GB10 injection) by the National Medical Products Administration. It details the product, the acceptance notice, and the potential impact and risks related to the drug development. The document is short (1064 characters) and is an announcement of a regulatory event related to drug development, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report of voting results, nor a regulatory certification or officer attestation. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a clinical trial application acceptance that does not fit other specific categories.
2025-09-29 Chinese
自愿披露关于人干扰素α1b吸入溶液纳入突破性治疗品种名单的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the company regarding the inclusion of a drug (human interferon α1b inhalation solution) into the breakthrough therapy designation list by the National Medical Products Administration (NMPA) in China. It provides details about the drug, its clinical trial status, and potential impact on the company. The document is a voluntary disclosure about a regulatory milestone related to drug development, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is an official announcement about a regulatory and product development update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-23 Chinese
中国国际金融股份有限公司关于科兴生物制药股份有限公司股东向特定机构投资者询价转让股份的核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from China International Capital Corporation Limited regarding the verification of a shareholder's inquiry-based transfer of shares to specific institutional investors of Kexing Biopharmaceutical Co., Ltd. It includes detailed information about the transfer process, pricing principles, investor qualifications, and compliance with relevant laws and regulations. The document is titled as a "核查报告" (verification report) and focuses on the legality, fairness, and compliance of the share transfer process. It is not an announcement of a report, nor is it a financial statement or earnings release. It is a standalone audit or verification report related to a specific transaction, fitting the category of Audit Report / Information (AR). Q3 2025
2025-09-19 Chinese
简式权益变动报告书（科益医药、邓学勤）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report" or "Simplified Report on Changes in Shareholding." It details the changes in shareholding percentages and numbers for the controlling shareholders of 科兴生物制药股份有限公司, including specific dates, share quantities, and methods of share reduction. It references relevant Chinese securities laws and regulations governing disclosure of shareholding changes. The document is not an annual report, earnings release, or management discussion, but a formal notification of changes in major shareholdings. This fits the definition of a Major Shareholding Notification (MRQ). The document length is sufficient and contains detailed data on shareholding changes, not just an announcement or a brief note. Therefore, the correct classification is MRQ with high confidence.
2025-09-19 Chinese
股东询价转让结果报告书暨持股5%以上股东权益变动触及5%整数倍的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a detailed announcement regarding a shareholder inquiry-based transfer of shares and changes in shareholding percentages exceeding 5%. It includes specifics about the transferor, transferee, share quantities, prices, and regulatory compliance statements. The content focuses on shareholding changes and transfer results rather than financial performance, management changes, or earnings. It is not a financial report, earnings release, or management discussion. The document fits the definition of a Major Shareholding Notification (MRQ) because it reports changes in significant share ownership levels crossing thresholds (5% multiples). The document length and detail confirm it is not a brief announcement or a report publication notice. Therefore, the correct classification is MRQ with high confidence.
2025-09-19 Chinese
股东询价转让定价情况提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (777 characters) regarding the preliminary pricing of a shareholder inquiry transfer of shares by Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. It includes details about the pricing, number of institutional investors involved, and risk warnings. There is no detailed financial data, no full report, and no mention of a report being attached or published. The content focuses on a capital transaction update related to share transfer pricing and shareholder information. This fits the category of Capital/Financing Update (CAP).
2025-09-15 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.